Evaluation of a bioimmuno assay for t-PA activity and its relation to PAI-1 activity and antigen levels

Fibrinolysis and Proteolysis

Volumn 12, Issue 6, 1998, Pages 340-346

  Rosen S ^a   Wejkum, L ^a   Billing Claeson, S ^a   Ghosh, R ^a   Grdic, K ^a   Chmielewska, J ^b   Meijer, P ^c   Kluft, C ^c   Tengborn, L ^d   Conkie, J ^e   Walker, I ^e  

^a Chromogenix AB   (Sweden)

^b PFIZER INC   (United States)

^c TNO   (Netherlands)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYCLONAL ANTIBODY; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD CLOT LYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HUMAN; IMMUNOASSAY; MALE; PRIORITY JOURNAL; REPRODUCIBILITY; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOSIS;

EID: 0032418253     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(98)80391-3     Document Type: Article

References (44)

1. 2-antiplasmin associated with severe hemorrhagic tendency. J Clin Invest 1979; 63: 877-884.
2. 2-antiplasmin. Blood 1982; 1169-1180.
3. Aoki N, Moroi Y, Sakata Y, Yoshida N, Matsuda M. A hereditary molecular abnormality found in a patient with recurrent thrombosis. J Clin Invest 1978; 61: 1186-1195.
4. Kazama M, Tahara C, Suzuki Z, Gohchi K, Abe T. Abnormal plasminogen, a case of recurrent thrombosis. Thromb Res 1981; 21: 517-522.
5. Soria J, Soria C, Bertrand O, Dunn F, Drouet L, Caen JP. Plasminogen Paris I: congenital abnormal plasminogen and its incidence in thrombosis. Thromb Res 1983; 32: 229-238.
6. Sartori MT, Patrassi GM, Girolami B, Girolami A. Type I plasminogen deficiency should probably be included among familial thrombophilias. Clin Appl Thrombosis/Hemostasis 1997; 3: 218-219.
7. Chmielewska J, Rånby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-436.
8. Kruithof EKO, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-913.
9. Verheijen JH, Chang GTG, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost 1984; 51: 392-395.
10. Thorsen S, Philips M. Isolation of tissue-type plasminogen activator-inhibitor complexes from human plasma. Biochim Biophys Acta 1984; 802: 111-118.
11. Juhan-Vague I, Pyke S, Alessi M, Jespersen J, Haverkate F, Thompson S. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94: 2057-2063.
12. Schleef RR, Higgins DL, Pillemer E, Levitt LJ. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 1989; 83: 1747-1752.
13. Diéval J, Nguyen G, Gross S, Delobel J, Kruithof EKO. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor Type 1. Blood 1991; 77: 528-532.
14. Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D. Complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 1992; 327: 1729-1733.
15. Carmeliet P, Collen D. Targeted gene manipulation and transfer of the plasminogen and coagulation systems in mice. Fibrinolysis 1996; 10: 195-213.
16. Rånby M, Norrman B, Wallén P. A sensitive assay for tissue plasminogen activator. Thromb Res 1982; 27: 743-749.
17. Verheijen JH, Mullart E, Chang GTG, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemost 1982; 48: 266-269.
18. Gyzander E, Eriksson E, Teger-Nilsson A-C. A sensitive assay for tissue plasminogen activator activity in plasma using adsorption on lysine Sepharose. Thromb Res 1984; 35: 547-558.
19. Nilsson K, Rosén S, Friberger P. A new kit for determination of tissue plasminogen activator and its inhibitor in blood. Fibrinolysis 1987; 1: 163-168.
20. Mahmoud M, Gaffney PJ. Bioimmunoassay (BIA) of tissue plasminogen activator (t-PA) and its specific inhibitor (t-PA/INH) Thromb Haemost 1985; 53: 356-359.
21. Mahmoud-Alexandroni M, Heath AB, Gaffney PJ. Sensitive and direct assays for functionally active plasminogen activators (tissue-type and urokinase-type) in plasma. Am J Clin Pathol 1989; 92: 308-314.
22. Meijer P, Boon R, Jie AFH, Rosén S, Kluft C. Bioimmunoassay for tissue-type plasminogen activator (t-PA) in human plasma: Evaluation of blood sampling and handling procedures and comparison with other t-PA activity methods. Fibrinolysis 1992; 6 (supp 3): 97-99.
23. Dahl KH, Klokk Holst J, Smith P, Gogstad GO. Functional measurement of t-PA in plasma using a bead immuno chromogenic assay (BICA). Fibrinolysis 1987; 1: 83-89.
24. Kluft C, Verheijen JH. Blood collection and handling procedures for assessment of plasminogen activators and inhibitors (Leiden Fibrinolysis Workshop). Fibrinolysis 1996; 10 (supp 2): 171-179.
25. Emeis JJ, Kooistra T. Interleukin 1 and lipoplysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163: 1260-1266.
26. Nordby E, Arnesen H, Andersson P, Godal H. Euglobulin clot lysis time, a rapid and sensitive method for the assay of fibrinolytic activity after venous stasis. Scand J Haematol 1980; 25:407-411.
27. Meijer P, Kret R, Bloetjes PTM, Rosén S, Kluft C. New aspects of blood collection and handling procedures for the assessment of t-PA and PAI-1 variables after the introduction of acid blood collection. Fibrinolysis 1994; 8 (supp 2): 145-147
28. Meade TW, Howarth DJ, Cooper J. Fibrinolytic activity and arterial disease. Lancet 1994; 343: 1442.
29. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 1993; 88: 2030-2034.
30. Hamsten A, Eriksson P. Fibrinolysis and atherosclerosis. Baillieres Clin Haematol 1995; 8: 345-363.
31. Ridker PM, Vaughan DE, Stampfer MJ. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1994; 341: 1165-1168.
32. Munkvad S, Gram J, Jespersen J. A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. Eur Heartl 1990; 11: 525-528.
33. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu K. Association of fibrinolytic parameters with early atherosclerosis. The ARIC study. Circulation 1995; 91: 284-290.
34. Rifón J, Páramo JA, Panizo C, Montes R, Rocha E. The increase of plasminogen activator inhibitor activity is associated with graft occlusion in patients undergoing aorto-coronary bypass surgery. Br J Haematol 1997; 99: 262-267.
35. Ridker PM, Hennekens CH, Stampfer MJ. Prospective study of endogenous tissue plasminogen activator and stroke. Lancet 1994; 343: 940-942.
36. Margaglione M, Di Minno G, Grandone E et al. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arterioscler Thromb 1994; 14: 1741-1745.
37. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. New Engl J Med 1995; 332: 635-641.
38. Kluft C. Constitutive synthesis of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1): conditions and therapeutic targets. Fibrinolysis 1994; 8(supp 2): 1-7
39. Bos R, Revet M, Niewenhuizen W. A bio-immuno assay to determine free tissue-type plasminogen activator (t-PA) in Stabilyte® plasma. Fibrinolysis 1994; 8(supp 2): 163-165.
40. Rånby M, Johansson G. A bio-functional immunoassay, BIA, for tissue plasminogen activator, tPA. Leiden Workshop on Fibrinolysis, April 1994.
41. Andreotti F, Kluft C. Circadian variation of fibrinolytic activity in blood. Chronobiology Int 1991; 8: 336-351.
42. Marckmann P, Bladbjerg E, Jespersen J. Dietary fish oil (4 g daily) and cardiovascular risk markers in healthy men. Arterioscler Thromb Vase Biol 1997; 17: 3384-3391.
43. Wallnofer AE, van Griensven JM, Schoemaker HC et al. Effect of isotretinoin on endogenous tissue-type plasminogen activator (t-PA) and plasmonogen activator inhibitor 1 (PAI-1) in human plasma. Thromb Haemost 1993; 70: 1005-1008.
44. Eliasson M, Evrin P-E, Lundblad D, Asplund K, Rånby M. Influence of gender, age and sampling time on plasma fibrinolytic variables and fibrinogen. Fibrinolysis 1993; 7: 316-323.